Studies examining hospital admissions and treatment for gout.
| Study | Yr(s) | Study Design | % Admissions for Gout of Total Hospital Admissions | Treatment of Acute Gout (%) | Urate-lowering Therapy (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prednisone | NSAID | Colchicine | ACTH | ULT at Admission | ULT Stopped | ULT Started | ULT Dose Increased | ULT Dose Decreased | Discharge Recommendations | ||||
| Our current study (NZ) | 2013–2014 | Retrospective note review | Primary diagnosis: 0.12% of acute admissions; secondary diagnosis: 0.15% admissions | 72.3 | 11.5 | 4.7 | 0 | 25.5 | N/A | 5.1 | 3.3 | N/A | 18.4% starting ULT advised to GP |
| Kennedy, et al10 (NZ) | 2012 | Retrospective note review | N/A | 61 | 40 | 40 | 15 | 50 | 31 | 11 | N/A | Advised to see GP et al10 36%, “treat-to-target” serum urate was initiated/recommended 9% | |
| Gnanenthiran, et al11 (Australia) | 2005–2006 | Retrospective note review | N/A | 28 | 32 | 75 | 1 | 26.9 | 56 | N/A | 19 | 8 | N/A |
| Petersel and Schlesinger14 (USA) | 2007 | Retrospective note review | N/A | 21 | 53 | 27 | 3 | N/A | N/A | N/A | N/A | ||
| Kamalaraj, et al12 (Australia) | 2008–2009 | Retrospective note review | N/A | 32.6 | 22.5 | 76.4 | 0 | 18 | N/A | N/A | N/A | N/A | N/A |
| Robinson, et al5 (NZ and England) | 1999–2009 | Administrative data | NZ 1999: 0.09% primary, 0.96 secondary; 2008–09: 0.11% primary, 0.26% secondary; UK 1999: 0.021%; 2008–09: 0.031% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NSAID: nonsteroidal antiinflammatory drug; ACTH: adrenocorticotropic hormone; ULT: urate-lowering therapy; NZ: New Zealand; GP: general practitioner; N/A: not assessed.